Premier Antibody Discovery Platform
Adimab (adimab.com) earns a Brand Analyzer score of 76 out of 100, placing it in the Brand-Ready tier among Healthcare brands, Technology brands. Among 2305 Healthcare brands analyzed, Adimab ranks in the 90th percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 100/100, Digital Presence 82/100, Visual Identity 96/100, Messaging Clarity 95/100, Trust Foundation 79/100, AI Discoverability 87/100, Brand Authority 26/100.
Adimab is a biotechnology company founded in 2007 and headquartered in Lebanon. It operates a proprietary yeast-based antibody discovery and engineering platform designed to accelerate the development of therapeutic antibodies. The platform combines fully human synthetic and immune libraries to produce highly specific, stable, and developable antibodies, supporting the creation of IgGs, heavy-chain antibodies (HCAbs), and multispecifics. Adimab serves biotech and pharmaceutical partners seeking preclinical-ready antibody leads.
| Brand Name | Adimab |
|---|---|
| Domain | adimab.com |
| Industry | Healthcare, Technology |
| Founded | 2007 |
| Headquarters | Lebanon |
| Main Competitors | AbCellera, Twist Bioscience, Ligand Pharmaceuticals, Humanigen, Iontas, Distributed Bio |
Moz Domain Authority 40/100 vs category average 29 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Accelerate antibody therapeutics with Adimab’s yeast-based antibody discovery and engineering platform built for developability and clinical success." (Meta description: 17 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 2 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on LinkedIn, Facebook, Instagram, GitHub; no detected presence on X (Twitter), YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Adimab scores 40/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Adimab has a limited AI-visibility profile at 40/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (62/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a Moz Domain Authority of 40/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and no llms.txt to steer AI to its best pages.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Adimab's main competitors include AbCellera, Twist Bioscience, Ligand Pharmaceuticals, Humanigen, Iontas. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Adimab official site
Adimab offers antibody discovery and engineering services centered on its proprietary yeast-based platform. Specific offerings include the use of fully human synthetic and immune libraries for antibody generation, production of IgGs, heavy-chain antibodies (HCAbs), and multispecific antibodies, as well as a full suite of integrated solutions designed to take a project from target identification to preclinical lead candidate. The platform emphasizes developability and suitability for clinical advancement.
Sources: Adimab official site
Adimab is a biotechnology organization founded in 2007 and headquartered in Lebanon. It is the developer of a proprietary yeast-based antibody discovery and engineering platform. The company positions itself as a premier partner for biotech and pharmaceutical companies seeking to develop reliable therapeutic antibodies, offering an integrated suite of solutions from target identification through preclinical lead generation.
Sources: Adimab official site
Adimab accelerates antibody therapeutics development using its yeast-based discovery and engineering platform. The platform combines fully human synthetic and immune libraries to deliver highly specific, stable, and developable antibodies. It supports the efficient production of IgGs, heavy-chain antibodies (HCAbs), and multispecific antibodies, guiding partners from initial target selection through preclinical lead identification with a full suite of integrated solutions built for developability and clinical success.
Sources: Adimab official site
Popular alternatives to Adimab include AbCellera, Twist Bioscience, Ligand Pharmaceuticals, Humanigen, Iontas. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Adimab official site
Adimab has limited AI-search visibility, scoring 40/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 49, recommendation 62). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Adimab official site
Adimab was founded in 2007. Adimab operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Adimab is headquartered in Lebanon. Adimab operates in the Healthcare category.
Sources: Wikidata
Adimab and AbCellera are competitors in Healthcare. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Adimab official site
Adimab is known for its proprietary yeast-based antibody discovery and engineering platform, which is built specifically for developability and clinical success. The platform is distinguished by its use of fully human synthetic and immune libraries, enabling the generation of highly specific, stable, and developable antibodies. Adimab is recognized as a premier resource for biotech and pharmaceutical partners seeking therapeutic antibody candidates ready for preclinical advancement.
Sources: Adimab official site
Adimab scores 62/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Adimab official site
Adimab's platform is used by biotech and pharmaceutical companies that are developing antibody therapeutics. These are organizations that require reliable, developable antibody candidates and seek an external platform partner to accelerate their discovery and engineering processes. Adimab positions itself specifically for these partners, offering services that support the journey from target identification through to preclinical lead generation in the therapeutic antibody space.
Sources: Adimab official site
Adimab can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Adimab official site
Based on the available facts, Adimab's appeal to biotech and pharmaceutical companies stems from its yeast-based platform's ability to deliver highly specific, stable, and developable antibodies efficiently. Its integrated solutions - spanning IgGs, HCAbs, and multispecifics - and its focus on developability and clinical success make it a practical partner for companies advancing antibody therapeutics. The platform's design around preclinical lead readiness addresses a key bottleneck in drug development.
Sources: Adimab official site
Ranked closest to Adimab: Zanda Health (77/100), Visible Body (77/100), Adit (76/100), Aspen Pharmacare (76/100).
A step up - brands to learn from: Zipline (81/100), Zimmer Biomet (81/100).
Category leader: Dassault Systèmes (95/100).